Can organ-age measurements help explain benefits beyond weight loss?

LinkedIn caption
📊 Can organ-age measurements help explain benefits beyond weight loss?
At ARDD 2026, Alejandro Aguayo-Orozco of Novo Nordisk discussed semaglutide analyses across major clinical trials. The official recap reports lower proteomic heart and kidney age scores from the earliest measured timepoint, with changes in more organs later. These biomarker changes were not fully explained by weight loss.
💡 The next question is how these molecular signals connect to clinical outcomes. Organ-age estimates remain distinct from a claim that aging has been reversed.
#ARDD2026 #Biomarkers
X caption
📊 At #ARDD2026, Alejandro Aguayo-Orozco explored semaglutide and proteomic organ-age scores, linking biomarker changes with clinical outcomes beyond weight loss. These changes were not fully explained by weight loss. The next question is how they relate to clinical outcomes.
Credit: Michael DeStefano
Copy and paste the caption manually, then attach the downloaded photo. Nothing is published automatically.